A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist SB-497115-GR Administered at 50, 75, and 100 mg to Cancer Patients receiving Multiple Cycles of Chemotherapy
- Conditions
- Treatment of chemotherapy induced thrombocytopenia with carboplatin and paclitaxel in advanced solid tumors.MedDRA version: 6.1Level: HLTClassification code 10029105
- Registration Number
- EUCTR2004-000368-28-IT
- Lead Sponsor
- GLAXO SMITHKLINE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 164
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method